ArticleEuropean radiology2017
Thoracic staging with
Article in European radiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- [Frontiers in medicine · 2024Pooled it
- Integrated versus separate reading of F-18 FDG-PET/CT and MRI for abdominal malignancies - effect on staging outcomes and diagnostic confidence.European radiology · 2019Trial
- Prospective comparison ofEuropean journal of nuclear medicine and molecular imaging · 2019Trial
- Review
- Limited Additional Value of a Chest CT in Whole-Body Staging with PET-MRI: A Retrospective Cohort Study.Cancers · 2024Article
- Review
- Consistency and prognostic value of preoperative staging and postoperative pathological staging usingAnnals of nuclear medicine · 2022Article
- State-of-the-art MR Imaging for Thoracic Diseases.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2022Review
- Perspective paper about the joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2022Review
- Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[European journal of nuclear medicine and molecular imaging · 2022Review
- An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases.European journal of nuclear medicine and molecular imaging · 2021Article
- Hybrid PET/MRI in non-small cell lung cancer (NSCLC) and lung nodules-a literature review.European journal of nuclear medicine and molecular imaging · 2021Review
- Thoracic positron emission tomography:Journal of thoracic disease · 2020Review
- Recent and Current Advances in FDG-PET Imaging within the Field of Clinical Oncology in NSCLC: A Review of the Literature.Diagnostics (Basel, Switzerland) · 2020Review
- Article
- Management implications of fluorodeoxyglucose positron emission tomography/magnetic resonance in untreated intrahepatic cholangiocarcinoma.European journal of nuclear medicine and molecular imaging · 2020Article
- Recent advances of PET imaging in clinical radiation oncology.Radiation oncology (London, England) · 2020Review
- Current Applications for Nuclear Medicine Imaging in Pulmonary Disease.Current pulmonology reports · 2020Review
- PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations.European journal of nuclear medicine and molecular imaging · 2020Article
- Impact of Computer-Aided CT and PET Analysis on Non-invasive T Staging in Patients with Lung Cancer and Atelectasis.Molecular imaging and biology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate whether differences in thoracic tumour staging between MATERIAL AND
methodsSeventy-seven NSCLC patients that underwent whole-body
resultsStaging results differed in 35 % of patients (27 patients) between thoracic PET/CT and PET/MR. Differences were detected when assessing the T-stage in 18 % (n = 14), the N-stage in 23 % (n = 18), and the M-stage in 1 % (n = 1). However, patient therapy management was changed in only six patients (8 %).
conclusionDespite the variability of thoracic KEY POINTS: • PET/CT and PET/MR provide comparable results in early stages in NSCLC • Clinical impact of different staging results has not been investigated • PET/CT and PET/MR lead to comparable therapeutic decisions • PET/MR can be considered an alternative to PET/CT for NSCLC staging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.